← All trials
NCT07028320
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 3, 2021
- Primary completion
- Dec 30, 2023
- Completion date
- May 20, 2024
- First posted
- Jun 19, 2025
- Last posted
- Jun 25, 2025
- Enrollment
- 493
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shenzhen Salubris Pharmaceuticals Co., Ltd.Lead sponsor
- Jiao Tong UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.